MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into clinical trials.
Our Pipeline of Investigational Drugs
THIO
THIO is a Telomere Targeting Agent that has been designed to selectively target tumor cells via Telomerase to cause damage...
MJC13
MJC13 targets the regulation of androgen receptor (AR) by binding to a recently identified regulatory surface on AR (BF3). MJC13 is...
GMC1
GMC1 is a FKBP52 co-chaperone-inhibitor for prostate cancer. GMC1 has been designed to engage a new pharmacologic target, FKBP52 (FK506...